Journal article
Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres
Journal of global antimicrobial resistance, v 22, pp 689-694
Sep 2020
PMID: 32353524
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
•We compared C/T and CZA activity against ESBL-producing Enterobacterales and β-lactam-resistant Pseudomonas aeruginosa.•β-lactamase genes were identified in Enterobacterales with increased C/T or CZA MIC values.•More than 90% of Enterobacterales isolates demonstrated susceptibility to both C/T and CZA.•Both agents were active against >80% of β-lactam-resistant P. aeruginosa isolates.
Despite availability of ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) for several years, the individual spectrum of activity of each agent may not be widely known. We compared the activity of C/T and CZA against convenience samples of 119 extended-spectrum β-lactamase (ESBL)-producing Enterobacterales and 60 β-lactam-resistant Pseudomonas aeruginosa clinical isolates collected from three U.S. institutions.
Minimal inhibitory concentrations (MICs) for C/T and CZA were determined by broth microdilution. Molecular identification of nine β-lactamase gene targets was conducted for Enterobacterales and P. aeruginosa isolates with increased MICs to C/T or CZA.
More than 90% of Enterobacterales isolates demonstrated susceptibility to both C/T and CZA, in contrast to the other traditional β-lactam agents tested, which were much less active. The MIC50/90 values were nearly equivalent between agents. The most common β-lactamase genes identified in Enterobacterales isolates with MIC values ≥2 mg/L were the CTX-M-1 group (85%) and CMY-2-like (23%) β-lactamases. Both agents were active against >80% of β-lactam-resistant P. aeruginosa isolates tested, most of which had oprD mutations identified. One P. aeruginosa isolate was positive for a Klebsiella pneumoniae carbapenemase-type gene but remained meropenem-susceptible. The MIC50 values were four-fold lower in favour of C/T (1 mg/L vs. 4 mg/L) against P. aeruginosa.
Our data suggest that either agent may be a reasonable choice for centres with a high proportion of ESBL producers; however, C/T may have improved activity against P. aeruginosa and may be preferred in institutions with a higher frequency of resistant pseudomonal isolates.
Metrics
Details
- Title
- Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres
- Creators
- Elizabeth B. Hirsch - University of MinnesotaHunter V. Brigman - University of MinnesotaPaola C. Zucchi - Northeastern UniversityAlice Chen - Northeastern UniversityJadyn C. Anderson - University of MinnesotaGeorge M. Eliopoulos - Beth Israel Deaconess Medical CenterNicole Cheung - Northeastern UniversityAdam Gilbertsen - University of MinnesotaRyan C. Hunter - University of MinnesotaChristopher L. Emery - Indiana UniversityTiffany E. Bias - Hahnemann University Hospital
- Publication Details
- Journal of global antimicrobial resistance, v 22, pp 689-694
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Web of Science ID
- WOS:000572210500037
- Scopus ID
- 2-s2.0-85088799478
- Other Identifier
- 991019330622104721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Infectious Diseases
- Pharmacology & Pharmacy